Alnylam Pharmaceuticals

Alnylam (NASDAQ: ALNY) is developing a novel class of drugs based on RNA interference, and is pursuing a range of targets in genetic medicine, cardio-metabolic disease, and hepatic infectious disease.

Headquarters Cambridge, MA
Website www.alnylam.com​​
Pipeline FDA-approved (US)